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ABSTRACT
Insulin human, containing 51 amino acids, is a small polypeptide hormone that regulates blood glucose homeostasis. Patients with
insulin-dependent diabetes mellitus require insulin therapy through the administration of exogenous insulin to avoid ketoacidosis. Utilizing
various genetic engineering techniques, pharmaceutical companies have developed a variety of rapid- or long-acting insulin analogues.
Analytical methods for various types of insulin and insulin analogues are gradually being included in the United States Pharmacopeia
(USP) and the European Pharmacopeia (Ph. Eur.), but not yet in the Chinese Pharmacopeia. Usually these insulin analogues only differ by
1 to 3 amino acids, which is too subtle to distinguish by most of analytical methods currently available. In this study a peptide mapping
technique was employed to screen insulin analogues for quality assessment. Peptide mapping is capable of identifying single amino acid
changes resulted from events such as errors in the reading of complementary DNA sequences or point mutations. Here we analyzed 6
insulin preparations including insulin human, insulin lispro, insulin aspart, insulin detemir, insulin glargine and insulin glulisine using
peptide mapping analysis. The peptide fingerprints of the insulin products we tested all corresponded well to those of the standard materials.
Our peptide mapping method is more accurate in identifying the subtle differences between the insulin analogues than chromatography is.
We concluded that peptide mapping is a valuable initial screening tool for quality assessment of insulin analogues. In the future, we intend
to continue to develop this technology for post-marketing surveillance of other biopharmaceuticals and biosimilars, such as somatropin,
erythropoietin and G-CSF.
Key words: insulin, insulin analogues, peptide mapping, high performance liquid chromatography

INTRODUCTION
Human Insulin is produced by the beta cells of the
pancreas, which are located in the islets of Langerhans(1).
Although insulin is active as a monomer, it assembles to
dimmers and hexamers in the presence of zinc during biosynthesis and storage(2). Because of its evolutionarily conserved
gene structure across species, insulin extracted from bovine
and porcine pancreas is given to people with diabetes mellitus
in early insulin therapy(3). Banting and Best extracted bovine
insulin in 1921 and successfully administered it to patients
with diabetes mellitus(4). After undergoing evolutionary
manufacturing, recombinant insulin was the first approved
biotechnology-derived drug product in 1982. Recombinant
insulin has subsequently replaced purified insulin from animal
sources in clinical therapy. Within 15 years, a further 5 insulin
analogues have been developed by pharmaceutical companies providing more choices for diabetes patients (Table 1).
* Author for correspondence. Tel: +886-2-2787-7752;
Fax: +886-2-2787-7799; E-mail: jiachuan@fda.gov.tw

All insulin analogues are modified from the insulin human
gene using genetic engineering techniques and produced in
E. coli or yeast. Amino acid substitution in insulin lispro,
insulin aspart, and insulin glulisine allows a more rapid onset
of action and shorter duration of activity. Long-acting basal
analogues such as insulin glargine and insulin detemir have
a slower onset of action and a longer duration of action(5,6).
Depending on disease progression, optional insulin therapy
can reduce injection frequency and side effects, and thus
improve quality of life(7).
Insulin human is a 2-chain polypeptide hormone
composed of 51 amino acids with a molecular weight of
5,808 Daltons (Figure 1A). The A-chain is composed of 21
amino acids and the B-chain is composed of 30 amino acids.
The 3-dimensional structure of insulin is further stabilized
by disulfide bridges between thiol groups (-SH) on cysteine
residues. Insulin has 6 cysteines that form 3 disulfide bridges:
2 form an interchain between the A and B chains (between
A7 and B7, and A20 and B19), and 1 forms an intrachain
within the A-chain (between A6 and A11)(8,9). Insulin lispro
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Table 1. Comparison of insulin human and insulin analogues
Name
MW(Da)
Acting
Host cell
Approval year

insulin human

insulin lispro

insulin aspart

insulin glargine

insulin glulisine

insulin detemir

5808

5808
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6063

5823

5916.9
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rapid

long

rapid

long
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E. coli

yeast
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Figure 1. Diagrams of structures and Glu-C proteinase V8 digestion sites of (A) insulin human, (B) insulin lispro, (C) insulin aspart, (D) insulin
detemir, (E) insulin glargine, and (F) insulin glulisine. Peptide fragments generated from protease V8 treatment were labeled as I, II, III, and IV. The
modification sites of insulin analogues are circled by dotted lines.

is identical in primary structure to insulin human, only
differing in amino acid sequence at positions 28 and 29 of
the B-chain. Insulin human is ProB28, LysB29, whereas insulin
lispro is LysB28, ProB29 (Figure 1B). As it has the same amino
acid composition, the molecular weight and charge value of
insulin lispro are the same as insulin human(10,11). Insulin
aspart has AspB28 instead of ProB28 (Figure 1C)(12). Because
of the change in amino acid composition, the molecular weight
of insulin aspart is slightly greater than that of insulin human
at 5,825.8 Daltons. Insulin detemir is a long-acting insulin
analogue in which a myristic acid is bound to the LysB29
and it has a molecular weight of 5,916.9 Daltons(13) (Figure
1D). Insulin glargine differs from insulin human in that the

amino acid AsnA21 is replaced by glycine and 2 arginines are
added to the C-terminus of the B-chain (Figure 1E)(14). It has
a molecular weight of 6,063 Daltons and an isoelectric point
of 6.7, which contrasts with the native insulin human, which
has an isoelectric pH of 5.4. The rapid acting profile of insulin
glulisine is achieved by substitution of 2 amino acids in the
B-chain of insulin human, where AsnB3 is replaced by Lys
and LysB29 is replaced by Glu (Figure 1F)(15). The amino acid
substitutions in insulin glulisine destabilise the hexamers and
therefore enable a faster onset of action than that achieved
with insulin human. The molecular mass of insulin glulisine
is 5,923 Daltons.
Since the insulin detemir, insulin glargine and insulin
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glulisine are not included in the pharmacopeia of various
countries, we consulted all the insulin-related monographs
in Ph. Eur. and USP to set up a standardized analytical
method which is available for their identification. In the Ph.
Eur. monographs the identification of the insulin human,
lispro, and aspart consists of a combination of 2 analytical
methods, the liquid chromatograms and peptide mapping. In
the USP monographs of insulin human and lispro the same
approach is used. In this study we set up a peptide mapping
method suitable for screening insulin human and all insulin
analogues. Peptide mapping is a method of identifying
proteins, especially those obtained by recombinant DNA
technology. It is a powerful test capable of identifying single
amino acid changes resulted from events such as errors in
point mutations and can be used to evaluate the stability of
the expression construct of cells used for recombinant DNA
products and the consistency of the overall process, and to
assess product stability, as well as to ensure the identity of the
protein product, or to detect the presence of protein variants
(16,17)
. We performed peptide mapping to evaluate the quality
of commercial insulin products, as well as a routine method
for post-marketing surveillance.

MATERIALS AND METHODS
I. Materials and Reagents
4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid
(HEPES) was purchased from Thermo Fisher Scientific
HyClone. HPLC grade acetonitrile, sequencing grade
endoproteinase Glu-C from S. aureus V8, ammonium
sulfate ((NH4)2SO4), hydrochloride (HCl), 3-methylphenol
(m-cresol), phenol, and sulfuric acid were purchased from
Sigma-Aldrich (St. Louis, MO). The Ph. Eur. reference standards of insulin human (batch number 3), insulin lispro (batch
number 1), and insulin aspart (batch number 1) were purchased
from the European Directorate for the Quality of Medicines &
HealthCare (EDQM). The in-house working standards were
obtained from Eli Lilly (insulin human and insulin lispro;
Indianapolis, IN), Novo Nordisk (insulin aspart and insulin
detemir; Princeton, NJ), and Sanofi-Aventis (insulin glargine
and insulin glulisine). The commercial products Humulin, in
which the active substance is insulin human, and Humalog, in
which active substance is insulin lispro, were obtained from
Eli Lilly. The commercial products NovoRapid, in which the
active substance is insulin aspart, and Levemir, in which the
active substance is insulin detemir, were obtained from Novo
Nordisk. Milli-Q grade water (Millipore, Milford, MA) was
used for buffer preparation and sample dilution. The Amicon
Ultra-0.5 3K Centrifugal Filter unit was purchased from
Millipore.
II. Enzymatic Digestion
Enzymatic digestion was performed according to the
procedure described in monograph of insulin human in the

European Pharmacopeia, with minor modifications. Briefly,
the digestion was carried out by diluting the insulin solution to
2.0 mg/mL with 0.01 M HCl and then transferring 170 mL of
this solution to a new tube. Six hundred and eighty microliter
of incubation buffer, 0.1 M HEPES, pH 7.5 adjusted with 5 M
NaOH, was added to the insulin solution. The digestion was
initiated by addition 136 mL S. aureus V8 endoproteinase,
which was prepared in water with a concentration of 1 mg/
mL. The digestion was carried out for 6 h at 25°C and then
quenched with 986 mL of sulfate buffer, which composed of
equal volumes of 2.0 M (NH4)2SO4 and 0.5 M sulfuric acid.
The final concentration of insulin in the digested sample solution was about 172 mg/mL. To investigate the alteration of
the excipients in the process of enzyme digestion, Amicon
Ultra-0.5 3K Centrifugal Units were used to remove most of
the preservatives and stabilizer in the formulation of insulin
products prior to the enzyme digestion. The digested protein
samples were analyzed immediately or stored at 4°C for
analysis within 48 h.
III. Reverse-Phase High Performance Liquid Chromatography
RP-HPLC was performed on a Dionex UltiMate 3000
HPLC system with a Diode Array Detector (USA). A 2-eluent
linear gradient system was employed with a flow rate of 0.8
mL/min. The mobile phase included water with 10% acetonitrile and 20% sulfate buffer as eluent A, and water with 40%
acetonitrile and 20% sulfate buffer as eluent B. The initial
condition was 5% eluent B for 3 min, and then 5-59% eluent
B from 3 to 30 min, 59-80% eluent B from 30 to 35 min,
80-5% eluent B from 35 to 40 min, and 5% eluent B left
for further 10 min to re-equilibrate. Fifty microliter digested
sample solutions were injected and analyzed on an Inertsil
ODS-3 C18 column (4.6×100 mm, 3 µm particle size; GL
Sciences, Japan) maintained at a column temperature of
40°C. Fractionated insulin and insulin analogue peptides
were detected by UV absorbance at 214 nm and compared
to the reference standards. Peak areas were calculated using
Chromeleon software (Dionex, USA).

RESULTS
First of all, the HPLC chromatograms of the intact insulin
human and insulin analogues were examined. The major
peaks of undigested insulin human and insulin analogues
were approximately overlapped indicating a high degree of
similarity between these molecules (Figure 2). In addition,
undigested insulin detemir could not be detected under our
standard analytical condition (Figure 2D). After that, peptide
mapping using a Glu-C proteinase for digestion and subsequent separation of the fragments by HPLC was employed.
To eliminate interference from these preservatives, a centrifugal filter was used to exclude molecules smaller than 3,000
Daltons before enzyme treatment. Although it was impossible to remove all the meta-cresol or phenol, filtering did
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lower the amount of preservatives considerably and did not
influence the retention time of the peptide fragments (data
not shown). Overall, since the preservatives did not affect the
enzyme activity, they were not removed to reduce artificial
errors in subsequent experiments.
Four peptide fragments were generated from insulin
human after protease V8 digestion and labeled as Fragment
I, II, III, and IV according to their molecular weight from
high to low (Figure 3A). Fragment I contained amino acids
A5-A17 and B1-B13, Fragment II A18-A21 and B14-B21,
Fragment III B22-B30, and Fragment IV A1-A4. These
4 peptide fragments eluted sequentially with the smaller
peptide fragments eluting more rapidly. Fragment IV of 4
amino acids eluted first in less than 5 min and showed the
lowest UV absorbance. Fragment III of 9 amino acids eluted
at about 21.4 min followed by Fragment II, which contained
12 amino acids, eluted from the column about 1.5 min later
than Fragment III. The UV absorbance of Fragment III was
detected at a similar level to that of Fragment II. Fragment I
containing 26 amino acids eluted at about 32 min and showed
the highest level of UV absorption.
Except for insulin glulisine, the amino acid modifications on insulin analogues do not alter the cleavage site of
Glu-C proteinase or the disulfide bonds, enzyme digested
insulin analogues produces a similar peptide map to insulin
human. A comparison of the peptide map of insulin lispro and
insulin human, revealed a remarkable shift in the retention
time of Fragment III that did not exist in the other 3 fragments
(Figure 3B). Fragment III of insulin lispro (LysB28-ProB29)
was eluted 2 min earlier than that of insulin human (ProB28LysB29). A similar phenomenon was revealed on the peptide
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Figure 2. Chromatograms of undigested Ph. Eur. reference standards (A) insulin human, (B) insulin lispro, (C) insulin aspart, and of undigested
in-house standards (D) insulin detemir, (E) insulin glargine, (F) insulin glulisine. (G) Chromatogram of undigested insulin mixture.
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Figure 3. Peptide mapping of (A) insulin human, (B) insulin lispro, (C)
insulin aspart, (D) insulin detemir, (E) insulin glargine, and (F) insulin
glulisine. Peptide fragments of insulin analogues different from those of
insulin human are indicated on the right side. Black arrows mark pyroglutamic acidA5 derived from Fragment I.
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maps of insulin aspart, where Fragment III of insulin aspart
(AspB28) was eluted 2 min earlier than that of insulin human
(ProB28) (Figure 3C). The peptide maps of insulin detemir
showed that Fragments I, II, and IV having identical retention
time to those of insulin human except Fragment III, which
was not detected in chromatogram (Figure 3D).
Insulin glargine showed a significant shift in the retention times of fragments II and III as compared with those of
insulin human (Figure 3E). Substitution of AsnA21 with Gly
on insulin glargine delayed the retention time of Fragment II.
Moreover, addition of 2 arginines on Fragment III of insulin
glargine (ArgB31-32) brought the elution ahead of that of
insulin human. Peptide Fragments II and IV of insulin glulisine were identical to those of insulin human, but Fragments
I and III were not (Figure 3F). Substitution of AsnB3 with Lys
on insulin glulisine made Fragment I elute earlier than that
of insulin human. Furthermore, substitution of LysB29 with
Glu on insulin glulisine provided an additional Glu-C endoproteinase cutting site on Fragment III, which was further
digested into one polypeptide B22-B29 and a single amino
acid threonineB30. Peptide fragment B22-B29 eluted about
2 minutes later than Fragment III of insulin human.

400
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I
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200
IV
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In order to verify that the insulin products contained
the same substances as the reference standards, the digested
insulin products were mixed with equal volume of the respective digested standards separately and the peptide maps of
the mixtures was analyzed (Figure 4). The results confirmed
the identity of the peptide fragments which presented only as
single peaks without duplicates. A control group experiment
was performed to verify the preservatives phenol and metacresol in the insulin products or in-house standards (data not
shown). In the absence of insulin glargine and insulin glulisine products, we did not compare the peptide map between
products and in-house standards.

DISCUSSION
Biopharmaceuticals are fundamentally different from
conventional small molecule chemical drugs in molecular
weight and complexity of the active substance, and even a
subtle change in the production process can have a critical
effect. The safety and efficacy profile of these biopharmaceutical products are highly dependent on the robustness
and various aspects of quality. For example, under improper
conditions asparagine deamidation can occur which generates aspartic acid and results in diminished bioactivity(15).
Currently, there is no method available for analyzing all the
protein impurities that may be present. A validated peptide
mapping method may provide a simple and accurate way to
detect protein variants (Table 2)(18).
All the peptide maps of analyzed commercial products
we tested were identical to their standards. Furthermore, a
comparison of the maps for various insulin analogues with
insulin human showed that even a single amino acid change
could be detected by peptide mapping. Comparing insulin
lispro with insulin human, Fragment III of insulin lispro
eluted earlier than that of insulin human suggested that the
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Figure 4. The insulin products (A) insulin human, (B) insulin lispro,
(C) insulin aspart, and (D) insulin detemir mixed with the equal volume
of their respective in-house standards separately were digested and
analyzed for identification.
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amino acid rearrangement might induce conformation change
and alter the retention time of peptide fragment. Single amino
acid substitution on insulin aspart changed the retention time
significantly, too. This phenomenon may be caused by the
increasing of peptide polarity due to the amino acid substitution from non-polar proline to polar and charged aspartic acid.
Fragment III of insulin detemir was not shown on the peptide
map, suggesting that the external fatty acid chain changed
the polarity of Fragment III and made it invisible under our
analytical condition. The reducing polarity on Fragment II of
insulin glargine caused by substitution of AsnA21 with Gly
resulted in delaying retention time. In contrast, additional 2
arginines on Fragment III increasing the polarity shortened
the retention time. In terms of insulin glulisine, substitution
of uncharged Asn with positive-charged Lys made Fragment
I elute earlier than that of insulin human. In addition, our data
showed that losing the polar amino acid threonine on Fragment III of insulin glulisine reduced polarity and extended the
retention time than that of insulin human.
With the exception of the insulin detemir, all the insulin
produced a single peak with a retention time of 34-35 min
without protease digestion. As there was a maximum difference of only 3 amino acids between insulin human and
insulin analogues, we thus concluded that the types of insulin
analogue could only be successfully indentified by peptide
mapping method. Peptide mapping technique displayed a
capability to reveal subtle differences and to distinguish
between insulin human and various types of insulin analogues
more effectively than liquid chromatography did. For particular structural modifications such as those that occur in insulin
detemir, the peptide mapping technique is also a useful tool
for unknown peptide fragment identification. In summary, if
reference standards are available, peptide mapping is a valuable initial screening tool not only for identification but also
for evaluation of biopharmaceuticals. However, to further
analyze impurities such as degradation products, host cell
protein residues and other contaminations, it is necessary to
develop other analytical tools.
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